Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3221-3224

  Lumachi, Franco ^a   Basso, Stefano M M ^a   Brandes, Alba A ^b   Pagano, Duilio ^a   Ermani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Breast cancer; CA 15 3; CEA; Hormone receptor; MIB 1

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROSTAGLANDIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANTIGEN DETECTION; BLOOD LEVEL; BREAST CANCER; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 6344226305     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. McGuire WL, Tandon AK, Allred DC et al: Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 70 (S1): 1775-1781, 1992.
2. Lumachi F, Brandes AA, Ermani M, Bruno G and Boccagni P: Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 20: 4751-4756, 2000.
3. Gion M, Barioli P, Mione R et al: Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Ann Oncol 6 (S2): S31-S35, 1995.
4. American Joint Committee on Cancer: Breast. In: AJCC Cancer Staging Handbook, sixth edition. New York: Springer-Verlag, 2002: 257-281.
5. Lumachi F, Brandes AA, Boccagni P et al: Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 19: 4485-4490, 1999.
6. Lumachi F, Ermani M, Brandes AA, Basso SMM, Basso U and Boccagni P: Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res 21: 4105-4108, 2001.
7. Ebeling FC, Schmitt UM, Untch M et al: Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer. Univariate and multivariate analysis. Anticancer Res 19: 2545-2550, 1999.
8. ASCO Report. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 15: 2149-2156, 1997.
9. Tabàr L, Duffy SW, Vitak B et al: The natural history of breast carcinoma: what have we learned from screening? Cancer 86: 449-462, 1999.
10. Bundred NJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137-142, 2001.
11. Harbeck N, Dettmar P, Thomssen C et al: Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187-2197, 1998.
12. Cooper LS, Gillett CE, Smith P, Fentiman IS and Barnes DM: Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Br J Cancer 77: 1502-1507, 1998.
13. Jones S, Clark G, Koleszar S et al: Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of patients. Clin Breast Cancer 1: 310-314, 2001.
14. Sikorska H, Schuster J and Gold P: Clinical applications of carcinoembryonic antigen. Cancer Detect Prevent 12: 321-355, 1988.
15. Given M, Scott M, Mc Grath JP and Given H: The predictive value of tumour markers CA 15-3 and CEA in breast cancer recurrence. Breast 9: 277-280, 2000.
16. Guadagni F, Ferroni P, Carlini S et al: A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7: 2357-2362, 2001.
17. Cartei G, Cartei F, Interlandi G et al: Preoperative circulating carcinoembryonal antigen in primary breast cancer: review of the literature and personal experience on 150 cases. Breast 5: 37-40, 1996.
18. Molina R, Filella X, Zanon G et al: Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 23: 1043-1050, 2003.
19. Safi F, Kohler I, Röttinger E and Beger HG: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 3: 574-582, 1991.
20. ASCO Expert Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: report of the American Society of Clinical Oncology expert panel. J Clin Oncol 14: 2843-2877, 1996.
21. ASCO Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.